- Home
- ROIV vs Q Comparison
ROIV vs Q Comparison
Compare ROIV & Q Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | Q |
|---|---|---|
| Founded | 2014 | 2024 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 26.4B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ROIV | Q |
|---|---|---|
| Price | $36.89 | $115.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $50.00 | ★ $174.20 |
| AVG Volume (30 Days) | ★ 6.2M | 1.5M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.31 |
| Revenue | $8,260,000.00 | ★ $4,754,000,000.00 |
| Revenue This Year | $593.33 | $18.63 |
| Revenue Next Year | $648.48 | $12.14 |
| P/E Ratio | ★ N/A | $93.35 |
| Revenue Growth | N/A | ★ 9.67 |
| 52 Week Low | $19.30 | $72.81 |
| 52 Week High | $42.50 | $177.28 |
Technical Indicators
Market Signals| Indicator | ROIV | Q |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 43.57 |
| Support Level | $33.11 | $112.54 |
| Resistance Level | $37.89 | $120.17 |
| Average True Range (ATR) | 1.25 | 4.67 |
| MACD | 0.32 | 0.12 |
| Stochastic Oscillator | 70.31 | 52.25 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About Q Qnity Electronics Inc.
Qnity is a specialty chemicals company created in 2025 after being spun off from DuPont. It sells chemicals and materials to the semiconductor industry, which generates the majority of sales, and also the electronics industry. Qnity specializes in materials science, including supplying key materials required to manufacture semiconductors and interconnected devices.